Clinical trial enablement services

Optimize trial design, site identification and patient recruitment for cardiometabolic disease trials with data-driven strategies

Cardiovascular disease (CVD) remains a leading cause of mortality worldwide, with lipoprotein(a) [Lp(a)] emerging as a critical risk factor. Despite its significance, Lp(a) is not routinely measured in clinical practice, making it difficult to identify and recruit eligible patients for atherosclerotic cardiovascular disease (ASCVD) related trials. In a crowded trial landscape, this lack of data creates a major barrier to enrollment. Access to rich diagnostic and operational data can transform how clinical trials are designed and implemented.  Data-driven strategies can help bridge this gap by enabling the location of high-risk individuals with known Lp(a) values, refinement of protocol criteria and placement of sites near patient clusters—accelerating recruitment and improving trial outcomes.

Key Takeaways

• Despite its known impact on cardiovascular disease (CVD), Lp(a) testing is still underutilized, creating additional complexity to design and recruit for studies
• Integrating data insights into a comprehensive enablement strategy helps accelerate timelines and reduce trial risk
• Access to robust diagnostic and operational data can help optimize protocols, identify high performing sites near potential patients and engage patients who may meet eligibility criteria

Access the whitepaper

Fill out the form to learn how a data-driven, patient-centered approach can help optimize trial design, streamline recruitment and accelerate timelines for cardiometabolic studies.